Zelboraf for thyroid cancer – pro
About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Zelboraf would need to be studied in thyroid cancer before being adopted. So far, there is only evidence from case reprots and an open label phase II study. IN it, Vemurafenib showed antitumour activity in patients with progressive, BRAFV600E-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor.
It is in a cinical trial: Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer, NCT01709292
Dr Marcia S Brose et al,Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet ONcology Volume 17, No. 9, p12721282, September 2016
NCCN, Thyroid Cancer 2017